Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077]
Res Pract Thromb Haemost. 2023 May 27;7(4):100191.
doi: 10.1016/j.rpth.2023.100191.
eCollection 2023 May.
1 Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, USA.
2 US Medical Affairs, Genentech Inc, South San Francisco, California, USA.
3 Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
4 Analystat Corporation, Point Roberts, Washington, USA.
5 Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
6 Department of Hematology and Medical Oncology and Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, Georgia, USA.
7 The Division of Coagulation, Georgetown University School of Medicine, Washington, DC, USA.
8 Division of Hematology, University of Washington and Washington Center for Bleeding Disorders, Seattle, Washington, USA.